Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis
J. Clin. Invest. Laurence M. Howard, et al. 109:233 doi:10.1172/JCI14374 [Go to this article.]

Figure 1
Short-term anti-CD154 mAb therapy causes long-term inhibition of EAE induction. (a) The indicated numbers of SJL mice were immunized with PLP139-151/CFA on day 0 and treated with 200 μg of either hamster IgG or anti-CD154 antibody (MR-1). Data represent combined results obtained from two separate experiments. *Disease incidence was significantly less (P < 0.0001) in anti-CD154–treated mice. (b and c) Mice immunized and treated with control Ig (b) or anti-CD154 (c) were sacrificed 105 days after immunization and sections were taken from lumbar and thoracic spinal cord sections, as described in Table 1. Sections demonstrate the continued normal appearance of spinal cord from anti-CD154–treated versus extensive immune cell infiltration, demyelination, and scarring observed in control Ig–treated mice.